PLK1 and breast neoplasm: The sensitivity to Plk1 inhibition toward p53-deficient tumors compared with that of wild type p53 tumors could potentially offer an opportunity to treat breast tumors that are refractory to standard chemotherapy such as basal-like TNBC.